<SEC-DOCUMENT>0001144204-19-046623.txt : 20191001
<SEC-HEADER>0001144204-19-046623.hdr.sgml : 20191001
<ACCEPTANCE-DATETIME>20191001080021
ACCESSION NUMBER:		0001144204-19-046623
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20191001
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		191127577

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv530209_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>October 1, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="logo_001.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LIPOCINE INC.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933&nbsp;(17 CFR &sect; 230.405) or&nbsp;Rule 12b-2 of the Securities
Exchange Act of 1934&nbsp;(17 CFR &sect; 240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to&nbsp;Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to&nbsp;Section 12(b)&nbsp;of the Act</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: Black 1pt solid; border-left: #CCCCCC 1pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: Black 1pt solid; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid; border-left: #CCCCCC 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LPCN</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosures</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will present data at The Liver Meeting&reg; 2019
of the American Association for the Study of Liver Diseases (&quot;AASLD&quot;) on November 8<SUP>th</SUP>-12<SUP>th</SUP> in Boston,
MA. The Company&rsquo;s materials to be used in the various presentations are attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 8.01</B></TD><TD STYLE="text-align: justify"><B>Other Events</B></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On October 1, 2019, Lipocine Inc. issued
a press release announcing the presentation of a LPCN 1144 Poster of Distinction at The Liver Meeting&reg; 2019 of the AASLD on
November 8<SUP>th</SUP>-12<SUP>th</SUP> in Boston, MA. The press release is filed as Exhibit 99.2 and are incorporated herein by
reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in">Item 9.01</TD><TD>Financial Statements and Exhibits.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv530209_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv530209_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Abstract &ldquo;LPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease<FONT STYLE="background-color: white">&rdquo;</FONT></FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv530209_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv530209_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release Announcing Presentation of LPCN 1144 Poster of Distinction at The Liver Meeting&reg; 2019 </FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 10%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 47%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">October 1, 2019</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv530209_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LPCN 1144 Resolves Non-Alcoholic Fatty
Liver Disease </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Somaya Albhaisi<SUP>1</SUP>, Kilyoung kim<SUP>3</SUP>,
Jonathan Baker<SUP>3</SUP>, Nachiappan Chidambaram<SUP>3</SUP>, Mahesh V. Patel<SUP>3</SUP>, Michael Charlton<SUP>4</SUP>, Arun
J. Sanyal<SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Dept of Internal Medicine, VCU, Richmond,
VA, USA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Div. of Gastroenterology, Hepatology
and Nutrition, Dept. of Internal Medicine, VCU, Richmond, VA, USA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Lipocine Inc., Salt Lake City, UT, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. University of Chicago Medicine, Chicago,
IL, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Background:
</B>Hypogonadism, defined by low circulating testosterone (T) levels, is increasingly being recognized in those with metabolic
syndrome, the principal risk factor for nonalcoholic fatty liver disease (NAFLD). Low T states are also seen in males with NAFLD.
However, it was not known if T replacement corrects NAFLD in these individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Aims:</B>
To determine (1) the prevalence of NAFLD in hypogonadal males, and (2) the effect of T-replacement on underlying NAFLD in hypogonadal
males.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Methods:
</B>A multicenter open label single-arm 16-week study of LPCN 1144, a testosterone prodrug, in hypogonadal males (n=138) was performed
with a subset (n=36) participating in liver fat assessment (NCT 03868059). Liver fat was assessed by MRI-PDFF and liver injury
from AST, ALT and GGT. NAFLD resolution was defined by MRI-PDFF &gt; 5% from baseline to end of study &lt; 5%. The effects of LPCN
1144 on liver enzymes were observed in the study of androgen replacement (SOAR) (NCT 02081300). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
<FONT STYLE="background-color: white"><B>Results:&nbsp; (1) Prevalence in hypogonadal males:</B> NAFLD prevalence, defined by MRI-PDFF
&gt; 5% was 62%, which is higher than that reported in the general population (Browning et al, Hepatology 2004). <B>(2) Effect
of LPCN 1144 on NAFLD:</B> NAFLD resolved in 33% of subjects at 8 weeks (mean relative reduction (RR): 45%) and 48% (mean RR: 55%)
by 16 weeks after starting LPCN 1144. The reduction in liver fat was greatest in those with highest baseline liver fat (BL<U>&ge;</U>
5%: 71%, BL<U>&ge;</U>8%: 80%, BL<U>&ge;</U>10%: 75%). Normalization rate of ALT and GGT were 100% and 50% of LPCN-1144 treated
patients respectively. Those with potential NASH (BL<U>&ge;</U>8%, n=10) had greater reduction in </FONT>AST (mean change: -2.5
U/L vs +0.3 U/L), ALT (-2.0 U/L vs -0.5 U/L) and GGT (-15.4 U/L vs -7.1 U/L) compared to the population as a whole. Similar findings
<FONT STYLE="background-color: white">were observed with the SOAR trial with normalization of liver enzymes in subjects with elevated
liver markers (ALT 52%, AST 50%, GGT 31%) but interestingly more significant for ALP (67%). No major adverse events occurred with
the use of the study drug. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Conclusions:
</B>Male hypogonadism is associated with NAFLD. Administration of the T-prodrug LPCN 1144 resolved NAFLD in half the affected patients
and normalized liver injury markers in those with elevated levels without any safety signals. These results warrant further assessment
of LPCN 1144 for the treatment of NASH in males with low T levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tv530209_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><IMG SRC="logo_002.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE TO PRESENT LPCN 1144 POSTER
OF DISTINCTION AT THE LIVER MEETING&reg; 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SALT LAKE CITY, UT, October 1, 2019 &ndash; Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that
data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease (&ldquo;NAFLD&rdquo;) will be presented at <FONT STYLE="color: Blue"><U>The
Liver Meeting<SUP>&reg;</SUP> 2019</U></FONT>. The Liver Meeting<SUP>&reg;</SUP> 2019, which is the annual meeting of the
American Association for the Study of Liver Diseases (&ldquo;AASLD&rdquo;), a leading organization of scientists and
healthcare professionals committed to preventing and curing liver disease, will be held on November 8th &ndash; 12th in
Boston, Massachusetts. Lipocine&rsquo;s abstract has been selected by the Scientific Program Committee of the AASLD as a
Poster of Distinction for presentation..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Presentation Details</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding: 0; text-indent: 0">Title:</TD>
    <TD STYLE="width: 75%; padding: 0; text-indent: 0">LPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Publication Number:</TD>
    <TD STYLE="padding: 0; text-indent: 0">#2121</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Date:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Monday, Nov 11, 2019</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Location:</TD>
    <TD STYLE="padding: 0; text-indent: 0">John B. Hynes Memorial Convention Center</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Time:</TD>
    <TD STYLE="padding: 0; text-indent: 0">8AM &ndash; 5:30PM ET</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lipocine Inc. is a clinical-stage biopharmaceutical company
focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development
pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs. TLANDO, a novel oral
prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal
men and currently under USFDA review for marketing approval. LPCN 1144, a differentiated oral product of bioidentical testosterone,
is currently undergoing Phase 2 clinical testing in biopsy confirmed NASH patients and recently completed a proof-of-concept clinical
study demonstrating the potential utility the in treatment of NASH. TLANDO XR (LPCN 1111), a novel oral prodrug of testosterone,
originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing
and has completed Phase 2 testing. LPCN 1148 is a unique oral testosterone product targeted to treat NASH cirrhosis. LPCN 1107
is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm
birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For
more information, please visit <FONT STYLE="color: Blue"><U>www.lipocine.com</U></FONT><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This release contains &quot;forward-looking
statements&quot; that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and
include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials, the timing
of completion of clinical trials, the potential uses and benefits of our product candidates, and our product development efforts.
Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation,
the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being
realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks
related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient
acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in
Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which
can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking
statements contained in this release, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For further information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Executive Vice President &amp; Chief
Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>mb@lipocine.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Hans Vitzthum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (617) 535-7743</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>hans@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ ,\# 2(  A$! Q$!_\0
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M1T/X4 >@5Y=\/-=UC6/$/B"UN]0FF2%6$*R-PAW$ BO4:\@^$W_(X^(_Q_\
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:3!BUK+YL>&QAL$<^O!-6J3:Z%0C)-W=S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logo_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ ,\# 2(  A$! Q$!_\0
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M1T/X4 >@5Y=\/-=UC6/$/B"UN]0FF2%6$*R-PAW$ BO4:\@^$W_(X^(_Q_\
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:3!BUK+YL>&QAL$<^O!-6J3:Z%0C)-W=S_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
